AdAlta Limited

Equities

1AD

AU0000001AD2

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:00:10 2024-04-25 pm EDT			5-day change	1st Jan Change
0.031 ^AUD	+6.90%		+10.71%	+29.17%

Apr. 08	AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	MT
Feb. 26	AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI

AdAlta delivers positive Phase I Extension Study results for AD-214

March 08, 2024 at 10:31 am EST

(via NewsDirect)

AdAlta Ltd (ASX:1AD) managing director Tim Oldham sits down with Proactive’s Jonathan Jackson to discuss encouraging outcomes from a Phase I extension study of their lead asset, AD-214, aimed at combating Idiopathic Pulmonary Fibrosis (IPF). This pivotal study assessed the target Phase II dose of AD-214 in healthy volunteers, marking a significant milestone in the drug's development pathway.The study's positive results have addressed the inquiries of potential partners. AD-214 exhibited a commendable safety profile, with consistent pharmacokinetics (PK) and pharmacodynamics (PD) across all doses and participants. This consistency bolsters confidence in the selected dose for Phase II studies. There was no evidence of adverse effects that could undermine efficacy, even with prolonged use, highlighting AD-214's potential as a treatment for IPF.With these results in hand, AdAlta is now engaging with a pipeline of potential partners to discuss licensing or asset financing transactions. Such agreements would provide the necessary support for the start of Phase II trials.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Latest news about AdAlta Limited

AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market	Apr. 08	MT
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
AdAlta-La Trobe University Collab Discovers New i-Bodies for Malaria Treatment; Shares Climb 4%	Dec. 18	MT
Adalta Posts Upbeat Results from Phase I Trial of Fibrotic Disease Drug	Nov. 22	MT
AdAlta Raises AU$1.7 Million Via Oversubscribed Placement; Shares Down 9%	Nov. 07	MT
AdAlta to Seeks AU$1.2 Million from Share Placement	Nov. 03	MT
AdAlta Receives AU$2.4 Million R&D Tax Rebate	23-10-18	MT
Adalta Completes Enrollment for Phase 1 Study on Fibrotic Disease Medication; Shares Fall 9%	23-09-20	MT
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-25	CI
Adalta Carries Out First Dosing in Phase One Extension Study of Fibrotic Disease Medication; Shares Jump 4%	23-08-03	MT
AdAlta Raises AU$1.9 Million Via Oversubscribed Shortfall Facility	23-07-13	MT
AdAlta Secures Ethics Approval for Phase One Clinical Trial	23-06-28	MT
AdAlta Raises AU$1.3 Million Via Rights Offer	23-05-24	MT
Adalta Limited Announces Retirement of Elizabeth Mccall as Non-Executive Director	23-03-23	CI
AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Journal of Biological Chemistry Highlights Potential of Adalta's i-Body Platform for Treating Osteoporosis	23-01-26	MT
Australian Researchers Demonstrate AdAlta's i-Body Platform's Treatment Potential for Osteoporosis	23-01-25	MT
Adalta Welcomes Two Investors Associated with Yuuwa Capital	23-01-24	MT
AdAlta Secures Second Patent for I-body Candidate	23-01-09	MT
AdAlta Limited Provides an Update on Its Lead Program, AD-214	22-11-01	CI
Australian Shares in the Red as US Fed Likely to Continue Rate Hikes	22-10-13	MT
Adalta, GPCR Therapeutics to Evaluate New Cancer Treatment Approach	22-10-12	MT
AdAlta Limited & GPCR Therapeutics, Inc. to Evaluate CXCR4 I-Bodies in Cancer	22-10-12	CI
AdAlta Receives $1 Million R&D Tax Rebate	22-10-04	MT
AdAlta Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-28	CI

Chart AdAlta Limited

Duration

Period

More charts

Company Profile

AdAlta Limited is an Australia-based clinical-stage drug discovery company. The Company is engaged in the development of therapeutic products from its i-body platform. The Company has five active development programs ranging from discovery to Phase II clinical trials with applications in the fields of inflammation/fibrosis and immuno-oncology. Its lead product, AD-214, is an antibody therapeutic for the treatment of fibrotic diseases, including lung fibrosis (specifically Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD)), kidney fibrosis, eye fibrosis and some cancers. Chimeric Antigen Receptor (CAR) cell therapies involve modification of a patientâs immune cells (T cells, NK cells, macrophages and other) so that they produce a CAR on the cell surface that enables the patientâs immune system to recognize and kill diseased cells such as cancer. It develops i-body enabled PET (i-PET) imaging agents for use in immuno-oncology. It evaluates several CXCR4 i-bodies.

Sector

Biotechnology & Medical Research

Calendar

2024-08-22 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADALTA LIMITED	+29.17%	10.63M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs